In a recent transaction, Boughton Soleil, the Chief Legal Officer of Hims & Hers Health, Inc. (NYSE:HIMS), sold 2,339 shares of Class A Common Stock. The shares were sold at an average price of $23.16, amounting to a total value of $54,171. Following this transaction, Soleil retains ownership of 169,935 shares in the company. This sale was conducted under a Rule 10b5-1 trading plan that Soleil adopted on September 10, 2023.
In other recent news, Hims & Hers Health, Inc. has seen several significant developments. Leerink Partners have upgraded their financial outlook for the company, raising the price target to $26.00, anticipating a robust revenue report for the quarter of $398.8 million. They also adjusted their EBITDA forecast, expecting $39.0 million. However, they expressed caution regarding the long-term sustainability of GLP-1 sales. BofA Securities also increased their price target for Hims & Hers, highlighting potential growth despite a deceleration in year-over-year sales.
The company also announced the appointment of Dr. Jessica Shepherd as the inaugural Chief Medical Officer of its Hers division, marking a strategic move to enhance its focus on personalized women's healthcare. Furthermore, Hims & Hers reported a robust 52% year-over-year revenue increase in Q2 2024, reaching $316 million, with an adjusted EBITDA of $39 million.
Analyst firms have also been active in their assessments of the company. Truist Securities maintained a Hold rating, citing the FDA's decision to revisit the shortage of Tirzepatide and the continued authorization for compounding pharmacies to produce its compounded version. Canaccord Genuity sustained its Buy rating on shares of Hims & Hers, highlighting the potential of its compounded GLP-1 medications amid rising obesity trends. These are among the recent developments shaping Hims & Hers' current business landscape.
InvestingPro Insights
While Hims & Hers Health's Chief Legal Officer has recently sold shares, the company's overall financial performance and market position remain strong. According to InvestingPro data, Hims & Hers Health has demonstrated impressive revenue growth, with a 50.15% increase in the last twelve months as of Q2 2024. This growth is further emphasized by the company's robust gross profit margin of 82.19% during the same period.
InvestingPro Tips highlight that Hims & Hers Health has been profitable over the last twelve months, and analysts predict the company will maintain profitability this year. This positive outlook is reflected in the stock's performance, with a strong return of 284.78% over the past year.
It's worth noting that the company is trading at a high earnings multiple, which could indicate investor confidence in future growth prospects. However, potential investors should be aware that Hims & Hers Health does not currently pay a dividend to shareholders.
For those interested in a deeper analysis, InvestingPro offers 14 additional tips for Hims & Hers Health, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.